Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 5/20 | 0.50 |
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 8/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GRK5 | P34947 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | PRKX | P51817 | 1/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15967703 | 1.00 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2MAOAMAOBS1PR5 | |
| SCHEMBL14555893 | 0.95 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2MAOAMAOBS1PR5 | |
| SCHEMBL14486508 | 0.95 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2MAOAMAOBS1PR5 | |
| SCHEMBL16592314 | 0.90 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2MAOAMAOBS1PR5 | |
| SCHEMBL14555953 | 0.84 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2MAOAMAOBS1PR5 | |
| SCHEMBL15967644 | 0.84 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2MAOAMAOBS1PR5 | |
| SCHEMBL14556031 | 0.81 | S1PR5 (0.52) | ALDH1A1SMN1; SMN2MAOAMAOBS1PR5 | |
| SCHEMBL14486475 | 0.81 | S1PR5 (0.52) | ALDH1A1SMN1; SMN2MAOAMAOBS1PR5 | |
| SCHEMBL16589447 | 0.81 | MAOA (0.49) | ALDH1A1MAOAMAOB | |
| SCHEMBL14486740 | 0.80 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2MAOAMAOBS1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729141-B1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR AGONISTS | Rottapharm Biotech Srl (IT) | 2015-12-09 | — | — | EP | disclosed |
| US-9181279-B2 | Cyclic amine derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-11-10 | — | — | US | disclosed |
| EP-2729445-B1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-10-21 | — | — | EP | disclosed |
| US-9120824-B2 | Cyclic amine derivatives as EP4 receptor agonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-09-01 | — | — | US | disclosed |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-03-26 | — | — | US | disclosed |
| US-20140243373-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR AGONISTS | ROTTAPHARM S.P.A. (IT) | 2014-08-28 | — | — | US | disclosed |
| EP-2729141-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR AGONISTS | Rottapharm S.p.A. (IT) | 2014-05-14 | — | — | EP | disclosed |
| EP-2729445-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm S.p.A. (IT) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013004290-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM S.P.A. (IT) | 2013-01-10 | — | — | WO | disclosed |
| WO-2013004291-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR AGONISTS | ROTTAPHARM S.P.A. (IT) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243373-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR AGONISTS | PTGER4, PTGER1, PTGIR | ALDH1A1 1634/4885SMN1; SMN2 4348/4885MAOA 785/4885 |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | ALDH1A1 2428/4885SMN1; SMN2 4790/4885MAOA 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.